Amgen Australia Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. QUICK FACTS Amgen focuses on areas of unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Full-Time Staff 147 (as at July 2014) Amgen in Australia • • • • • • Established in 1991. Corporate headquarters located in North Ryde, Sydney, New South Wales. Currently markets eight products in Australia for the treatment of cancer, kidney disease, bone disease and other serious illnesses. Is amongst the highest contributing countries to clinical trial activity by Amgen globally Invests approximately A$35 million in local research and development annually. In 2013 Amgen Australia was ranked as the 16th Greatest Place to Work in Australia. Research and Development (R&D) Since 1980, Amgen has been a leading innovator in the identification, isolation, production and use of human proteins as therapeutic agents. Today, our scientists work at the cutting edge between the traditional disciplines of chemistry and cellular and molecular biology in an effort to discover and develop the medical breakthroughs of tomorrow. Our focus is to pioneer treatments for serious illness and our R&D organisation has cultivated expertise in multiple treatment modalities – large-molecule proteins, small molecules and antibodies – allowing us to choose the best target for attacking disease and to use the modality most likely to affect that target. Clinical Trials Australian patients have access to Amgen’s medicines through clinical trials, which have been conducted in Australia for over 20 years. Through its significant clinical presence, Amgen Australia conducts on average two First in Human (FIH) studies every year and almost half of its clinical trial activity is in early phase research. In 2013, we conducted 76 different studies at 368 sites across Australia and New Zealand, involving 1,547 patients trialling Amgen’s innovative medicines. Amgen Australia invests around A$30-35 million in local research and development annually, which represents around 15% of its sales – this is very high compared with the industry average. One third of Amgen Australia’s workforce is involved in research and development. July 2014 Page 1 Primary Locations Head Office – Sydney Research & Development – Melbourne Contact Details Head Office (Sydney) Amgen Australia Pty Ltd Level 7, 123 Epping Road North Ryde NSW 2113 Australia T: + 61 2 9870 1333 F: + 61 2 9870 1344 Web: www.amgen.com.au ABN 31 051 057 428 Key Contact Medical Communications Phone: 1800 803 638 (toll free) Products • Aranesp® (darbepoetin alfa) • Neulasta® (pegfilgrastim) • NEUPOGEN® (filgrastim) • Nplate® (romiplostim) • Prolia® (denosumab) • Sensipar® (cinacalcet) • Vectibix® (panitumumab) • XGEVA® (denosumab) Amgen’s Workforce DID YOU KNOW? While Amgen established offices in Australia in 1991, clinical research in the region actually started much earlier. In 1987, clinical trial work for NEUPOGEN® (supportive treatment for cancer patients) was carried out in Royal Melbourne Hospital. Amgen Australia contributes disproportionately to the global clinical trial effort by being in the top three countries for active clinical studies. At any one time, Amgen Australia is involved in over 25% of active studies in the global clinical trial program. Amgen Australia also consistently contributes 5 percent of patients to the global pool of Amgen studies in which the affiliate participates. Globally Amgen employs approximately 20,000 staff worldwide and generates revenue of US$18.7 billion (2013). In Australia, 2013 revenue was approximately A$249 million. OUR MISSION AND VALUES Amgen strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or even save lives. In everything we do, we aim to fulfill our mission to serve patients. And every step of the way, we are guided by the values that define us. OUR MISSION: TO SERVE PATIENTS OUR VALUES: o o o o o o o o Be Science-Based Compete Intensely and Win Create Value for Patients, Staff, and Stockholders Be Ethical Trust and Respect Each Other Ensure Quality Work in Teams Collaborate, Communicate and Be Accountable July 2014 Page 2 Flexible workplace practices are the centrepiece of Amgen’s employee benefits. We have a diverse, equal opportunity workforce where 75% are female and the Country Management Team has significant female representation (4 out of 9 are female). Permanent employees enjoy an extensive range of benefits which include additional superannuation contributions, charity leave, a mentoring program, 25 days annual leave after five years and 12 weeks paid parental leave. Every employee is also a shareholder in the company. Work/life balance is addressed with a number of programs. Our “FlexAbility” program offers more flexible ways to work such as work from home, staggered start and finish times; time off in lieu for work conducted over weekends and Family and Friends Fridays (early finish at 2.00pm on one Friday each month). Career development is supported through the Amgen Global Career Framework and annual Individual Development Plans. Development opportunities range from project work, working on cross-functional teams to secondment, training programs for managers and all staff at Amgen, and study assistance. Employee Wellness is a priority, and Amgen provides free counselling services (Employee Assistance Program), wellness health checks and flu vaccinations to all staff. Amgen Australia – A Great Place to Work In June 2013 Amgen Australia was officially acknowledged as the 16th Greatest Place to Work in Australia, according to the Great Place to Work Institute. This was the third year running (ranked 25th in 2011, and 12th in 2012) that Amgen has been recognised on the distinguished list. The companies who made the coveted list were chosen based on a rigorous and highly competitive selection process across five dimensions including credibility, respect, fairness, pride and camaraderie. Amgen in the Australian Community At Amgen we believe we can play a role in contributing to a sustainable social sector that builds strong community connections, encourages employee volunteer programs and promotes organisational mentoring. For the past four years Amgen has partnered with United Way, a not-for-profit organisation that leads, supports, and participates in community efforts that build capacity and mobilise resources to improve lives and create positive, long-term social change in local communities. Along with our financial funding, Amgen offers a two-day paid charity leave program to all permanent staff via a range of volunteer activities that support organisations through United Way such as Glebe Centipede, RSPCA, Red Cross, Scope and Irabina Childhood Autism Services. We also support Osteoporosis Australia, Rare Cancers Australia and Kidney Health Australia with the latter focused on indigenous health. Amgen Australia Pty Ltd, ABN 31 051 057 428, Level 7, 123 Epping Road, North Ryde, NSW 2113 AUS2123
© Copyright 2024 ExpyDoc